- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Data Show Overall Response of 68 Percent in Patients with Relapsed or Refractory Disease
New Long-Term Study Suggests Lower Mortality in Alzheimer’s Patients Treated with Galantamine Versus Placebo
Significantly Lesser Cognitive Decline Also Seen in Treatment Group Compared to Placebo Group
Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings
Policy Aims to Support a Sustainable Supply of Medically Acceptable Generic Darunavir in Sub-Saharan Africa (SSA) and Least Developed Countries (LDC)